GRAIL (GRAL) Stock Forecast: What Could Drive It in 2026
Last updated July 2026
Short answer
What is actually driving GRAIL (GRAL) right now is Galleri volume and revenue growth: Galleri test volume grew roughly 50% year over year in Q1 2026 to more than 56,000 tests, and Galleri revenue rose about 37% to roughly $39.8 million. Revenue (TTM) is ~$156M. If that keeps playing out, the setup is favourable; the risk to it is gRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. No one can predict where GRAL trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive GRAIL (GRAL) higher?
1. Galleri volume and revenue growth
Galleri test volume grew roughly 50% year over year in Q1 2026 to more than 56,000 tests, and Galleri revenue rose about 37% to roughly $39.8 million. Management reiterated full-year revenue growth guidance in the low-to-mid 20s percent range. Continued volume compounding is the core driver of the equity story.
2. FDA approval pathway
GRAIL submitted a PMA application for Galleri to the FDA in January 2026, and the agency accepted it for review. An approval would be the first for a true blood-based multi-cancer screening test and would open the door to guideline inclusion and broad payer coverage. The timing and outcome of that review is the single largest swing factor for the stock.
3. Reimbursement and distribution reach
Galleri is still largely cash-pay, so the shift to insurance and Medicare coverage is what could unlock mass adoption. GRAIL announced an Epic electronic-health-record integration that lets physicians order Galleri and view results across a large base of health systems, expanding the ordering funnel ahead of any coverage decisions.
4. Clinical evidence base
Large studies such as the PATHFINDER 2 study (~35,000 participants) and the NHS-Galleri trial (~140,000 participants) are generating the outcomes data that guidelines committees and payers require. Positive readouts strengthen the case for approval and coverage, while disappointing data on real-world detection or false positives would undercut the thesis.
What could weigh on GRAL?
GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. The business is concentrated in essentially one product, Galleri, which leaves it exposed to any single negative FDA, clinical, or reimbursement outcome. Competition in multi-cancer detection is intensifying from Exact Sciences (Cancerguard), Guardant Health (Shield), Freenome, and others. Cash burn is heavy (operating cash flow was roughly negative $290 million over the trailing year), and if approval or coverage is delayed, the company may need to raise capital, which could dilute shareholders. The stock is also volatile and trades on a high price-to-sales multiple with no earnings support.
Where GRAL trades today
A forecast starts from where the stock actually is. These are GRAL's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for GRAL as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a GRAL forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the GRAL guide and whether GRAL is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the GRAL outlook
The bottom line: what is driving GRAIL (GRAL) is Galleri volume and revenue growth, with revenue (ttm) at ~$156M. If that keeps playing out the setup is favourable; the risk is gRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. No one can predict the price, so treat any GRAL forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around GRAL with Walnut
Use GRAIL as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for GRAIL (GRAL)?
+
No one can reliably predict where GRAL will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push GRAIL higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive GRAL higher?
+
The main growth drivers are Galleri volume and revenue growth; FDA approval pathway; Reimbursement and distribution reach. Whether they play out is the real question, not a guaranteed path.
What are the risks to GRAL?
+
GRAIL is unprofitable, posting a net loss of roughly $93 million in Q1 2026 and a trailing-twelve-month loss near $395 million, so it depends on its cash balance and eventual funding rather than current earnings. The business is concentrated in essentially one product, Galleri, which leaves it exposed to any single negative FDA, clinical, or reimbursement outcome. Competition in multi-cancer detection is intensifying from Exact Sciences (Cancerguard), Guardant Health (Shield), Freenome, and others. Cash burn is heavy (operating cash flow was roughly negative $290 million over the trailing year), and if approval or coverage is delayed, the company may need to raise capital, which could dilute shareholders. The stock is also volatile and trades on a high price-to-sales multiple with no earnings support.
Will GRAL stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. GRAIL's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is GRAL a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the GRAL "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.